Lilly's Tirzepatide Hits On Phase III, But Poised To Face A Crowded Diabetes Market

 
• By Joseph Haas
  
Diabetes
Lilly's initial Phase III data for its dual GIP/GLP-1 agonist look competitive
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D